Received more than 70 million yuan in Pre-A round financing and project funding to accelerate the research and development of innovative cancer drugs driven by organoids and AI.

The first pipeline of targeted drugs for diffuse gastric cancer obtained the Orphan Drug Designation from the US FDA.

After obtaining the IND approval from the US FDA, the pipeline of targeted drugs for diffuse gastric cancer obtained the approval for clinical trials from the National Medical Products Administration (NMPA) three weeks ahead of schedule.

The globally first pipeline of targeted drugs independently developed for the treatment of diffuse gastric cancer obtained the IND approval from the US FDA.

Won the first prize in the final of the MIT Technology Review China AI+ Entrepreneurship Competition.

Ranked on the Forbes Asia "100 to Watch" list, and it is one of only 11 enterprises from all industries in the Chinese mainland to be on the list.

The Organoid Model Animal Center was inaugurated and established, which is the first platform in Futian District, Shenzhen that can provide organoid and model animal services to the society.

Received tens of millions of yuan in Series Angel++ financing from Songhe Capital.

Received nearly ten million US dollars in Series Angel+ financing, led by GSR Ventures, with participation from Arisaig Partners and Blue Ocean Capital, and continued investment from Primavera Capital Group, Cloud Nine Capital, etc. This event was recommended on the homepage of Fierce Biotech, a leading biotech media in the United States.

Received 60 million yuan in Series Angel financing, led by Primavera Capital Group, with participation from many investment institutions such as Lihe Venture Capital, XtalPi, and Cloud Nine Capital.

The founding team is from the Dana-Farber Cancer Institute of Harvard University. They first discovered a powerful target for diffuse gastric cancer, which quickly filled the gap in this field. Cogency Biosciences was officially established.